TNFRSF8 and anaplastic large cell lymphoma: ALCANZA demonstrated an improvement in ORR (ORR: 56.3% in the BV arm vs. 12.5% in the conventional therapy arm),83 leading to FDA approval for the treatment of adult patients with primary cutaneous ALCL or CD30+ MF.